Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs Total potential deal value up to $2 billion plus tiered royalties on commercial sales Synaffix to provide Amgen access to its proprietary antibody-drug conjugate (ADC) technologies AMSTERDAM, THE NETHERLANDS, 5 January 2023 &m...